Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Amid Growth, Reckitt To Launch Mucinex In Emerging Markets Ahead of EU

This article was originally published in PharmAsia News

Executive Summary

Emerging markets, the key driver for Reckitt Benckiser's nearly 20 percent net income growth, will be crucial in the firm's launch of Mucinex decongestants outside the U.S

You may also be interested in...



Amid Controversy, Reckitt Clinches Paras Brands As India's OTC Drug Market Heats Up

MUMBAI - Outbidding at least six serious rivals, London-headquartered consumer and healthcare products giant Reckitt Benckiser paid a hefty $742 million to clinch the acquisition of India's Paras Pharma - a company that created strong OTC healthcare brands mainly through large-scale mass media campaigns over the last 10 years

Amid Controversy, Reckitt Clinches Paras Brands As India's OTC Drug Market Heats Up

MUMBAI - Outbidding at least six serious rivals, London-headquartered consumer and healthcare products giant Reckitt Benckiser paid a hefty $742 million to clinch the acquisition of India's Paras Pharma - a company that created strong OTC healthcare brands mainly through large-scale mass media campaigns over the last 10 years

Reckitt CFO Day departs

Colin Day, Reckitt Benckiser's chief financial officer for 10 years, will leave the organization, the U.K. company says Oct. 22. Day, who as CFO has seen the firm significantly expand its pharmaceutical business, will remain in the position until March 2011 to ensure a smooth transition. A successor will be announced in the next few months, the firm said

Related Content

Latest News
See All
UsernamePublicRestriction

Register

SC073489

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel